Abstract:OBJECTIVE:To evaluate effect of duration of clopidogrel use on clinical follow-up outcomes in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. METHODS:A total of 214 patients with acute myocardial infarction undergoing primary percutaneous coronary intervention between January 2005 to December 2007 were enrolled. All patients were divided into two groups by duration of clopidogrel use: <1 year group (n=59) and > or =1 years group (n=155). Baseline characteristics [age, gender, angiographic characteristics, Killip classification, LVEF (left ventricular ejection fraction) , CK (creatine kinase), CK-MB, CTnI (cardiac troponin-I), hemoglobin levels and history of hypertension, diabetes, hyperlipidemia, obesity and smoking] of two groups were collected. Clinical follow-up end-point was major adverse cardiac event (MACE) including death, acute myocardial infarction, stent thrombosis and stent restenosis. Clinical follow-up duration was 41.6 +/- 16.3 months. MACE occurred in 28 patients. RESULTS:Rates of male, infarction site, infarction relative artery, multivessel disease, Killip classification (class I), aspirin use and history of smoking, obesity, hypertension and hyperlipidemia were not different (P > 0.05) in duration of clopidogrel use <1 year group and > or =1 years group. Average LVEF, hemoglobin levels and rate of drug-eluting stents were significantly lower in duration of clopidogrel use <1 year group than that in duration of clopidogrel use > or =1 years group (P < 0.0001, P < 0.0001, P = 0.0065). Average CK, CK-MB, CTnI were significantly higher in duration of clopidogrel use > or =1 years group than that in duration of clopidogrel use <1 year group (P < 0.0001). Rate of diabetes and average age were significantly higher in duration of clopidogrel use <1 year group than that in duration of clopidogrel use > or =1 years group (P = 0.0190, P < 0.0001). Incidence of MACE in follow-up period was significantly lower in duration of clopidogrel use > or =1 years group than that in duration of clopidogrel use < 1 year group (6.45% vs. 30.51%, P < 0.01). After stopping clopidogrel use, incidence of MACE in followup period was significantly lower in duration of clopidogrel use > or =1 years group than that in duration of clopidogrel use <1 year group (2.58% vs. 20. 34%, P < 0.01). CONCLUSION:Primary percutaneous coronary intervention is an effective therapeutic method. Incidence of MACE in follow-up period was significantly lower in duration of clopidogrel use > or =1 years group than that in duration of clopidogrel use <1 year group. Duration of clopidogrel use may influence clinical outcomes in follow-up period in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.

Observation of the Enduring Efficacy and Safety of Domestic Clopidogrel Hydrogen Shlfate Tablets Applied to Patients after PCI

Safety and efficacy of domestic clopidogrel on patients with acute coronary syndrome after implantion of multiple coronary stents

Clinical effect of ticagrelor administered in acute coronary syndrome patients following percutaneous coronary intervention.

Clinical Efficacy of Domestic and Imported Clopidogrel for the Treatment of Patients Received PCI Associated with Low Left Ventricu-lar Ejection Fraction

[Effect of duration of clopidogrel use on clinical follow-up outcomes in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention].

The Short-Term Curative Effects of High Loading Dose of Clopidogrel Before Percutaneous Coronary Intervention Operation

Clinical analysis of clopidogrel resistance in patients with coronary heart disease after percutaneous coronary intervention

Efficacy of ticagrelor and clopidogrel in patients with acute coronary syndrome after elective percutaneous coronary intervention

Use of Ticagrelor As Antiplatelet Therapy in Patients with Unstable Angina Pectoris after Undergoing Percutaneous Coronary Interventions:A Clinical Observation

A retrospective study of the safety and efficacy of clopidogrel versus aspirin monotherapy one year after coronary stent implantation

Long-term Outcome Analysis of Patients Underwent Percutaneous Coronary Intervention with Prior Ischemic Stroke

A High Maintenance Dose of Clopidogrel Improves Short-Term Clinical Outcomes in Patients with Acute Coronary Syndrome Undergoing Drug-Eluting Stent Implantation

Observation of Ticagrelor Efficacy in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-elevation Myocardial Infarction

Treatment Outcomes of Clopidogrel in Patients with ACS and Diabetes Undergoing PCI-Analysis of Beijing Municipal Medical Insurance Database.

Aspirin in combination with clopidogrel in the treatment of acute myocardial infarction patients undergoing percutaneous coronary intervention

Long-term Dual Antiplatelet-Induced Intestinal Injury Resulting in Translocation of Intestinal Bacteria into Blood Circulation Increased the Incidence of Adverse Events after PCI in Patients with Coronary Artery Disease.

Efficacy and Safety of Aspirin Combined with Low-Dose P2Y12 Receptor Antagonists in East Asian Patients Undergoing PCI

Short-term Outcomes of High Loading Dose Clopidogrel Pretreatment Before Coronary Stenting in Patients with Acute Coronary Syndromes

Ticagrelor Versus Clopidogrel in the treatment of Elderly Chinese Chronic Total Occlusion Patients Undergoing Percutaneous Coronary Intervention

Abstract 15223: Comparison of Net Clinical Benefit Between Clopidogrel-based and Ticagrelor-based Dual Antiplatelet Therapy in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention in China

Long-term effect of triple antiplatelet therapy for diabetic patients after percutaneous coronary intervention